R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.66, issue.1, pp.7-30, 2016.

A. W. Hoffman, C. Ibarra-drendall, V. Espina, L. Liotta, and V. Seewaldt, Ductal carcinoma in situ: challenges, opportunities, and uncharted waters, Am Soc Clin Oncol Educ Book, vol.2012, pp.40-44

M. Morrow, S. J. Schnitt, and L. Norton, Current management of lesions associated with an increased risk of breast cancer, Nat Rev Clin Oncol, vol.12, issue.4, pp.227-265, 2015.

J. M. Pang, K. L. Gorringe, and S. B. Fox, Ductal carcinoma in situ -update on risk assessment and management, Histopathology, vol.68, issue.1, pp.96-109, 2016.

A. Spira, M. L. Disis, J. T. Schiller, E. Vilar, T. R. Rebbeck et al., Leveraging premalignant biology for immunebased cancer prevention, Proc Natl Acad Sci, vol.113, issue.39, pp.10750-10758, 2016.

P. Savas, R. Salgado, C. Denkert, C. Sotiriou, P. K. Darcy et al., Clinical relevance of host immunity in breast cancer: from TILs to the clinic, Nat Rev Clin Oncol, vol.13, issue.4, pp.228-269, 2016.

L. Pusztai, T. Karn, A. Safonov, M. M. Abu-khalaf, and G. Bianchini, New strategies in breast cancer: immunotherapy, Clin Cancer Res, vol.22, issue.9, pp.2105-2115, 2016.

S. R. Lakhani, I. O. Ellis, S. J. Schnitt, and P. H. Tan, WHO classification of Tumours of the breast, 2012.

R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen et al., The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group, Ann Oncol, vol.26, issue.2, pp.259-71, 2014.

D. C. Allred, J. M. Harvey, M. Berardo, and G. M. Clark, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol, vol.11, issue.2, pp.155-68, 1998.

A. C. Wolff, M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. Mcshane et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathol Lab Med, vol.138, issue.2, pp.241-56, 2014.

A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thurlimann et al., Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer, Ann Oncol, vol.22, issue.8, pp.1736-1783, 2011.

F. Kwiatkowski, M. Girard, K. Hacene, and J. Berlie, Sem: a suitable statistical software adaptated for research in oncology, Bull Cancer, vol.87, issue.10, pp.715-736, 2000.

A. H. Lee, L. C. Happerfield, L. G. Bobrow, and R. R. Millis, Angiogenesis and inflammation in ductal carcinoma in situ of the breast, J Pathol, vol.181, issue.2, pp.200-206, 1997.

M. R. Hussein and H. I. Hassan, Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations, J Clin Pathol, vol.59, issue.9, pp.972-979, 2006.

A. Lal, L. Chan, S. Devries, K. Chin, G. K. Scott et al., FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast, Breast Cancer Res Treat, vol.139, issue.2, pp.381-90, 2013.

E. Thompson, J. M. Taube, H. Elwood, R. Sharma, A. Meeker et al., The immune microenvironment of breast ductal carcinoma in situ, Mod Pathol, vol.29, issue.3, pp.249-58, 2016.

M. J. Campbell, F. Baehner, T. O'meara, E. Ojukwu, B. Han et al., Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast, Breast Cancer Res Treat, 2016.

M. M. Black, R. E. Zachrau, B. F. Hankey, and E. J. Feuer, Prognostic significance of in situ carcinoma associated with invasive breast carcinoma. A natural experiment in cancer immunology?, Cancer, vol.78, issue.4, pp.778-88, 1996.

H. Ben-hur, O. Cohen, D. Schneider, P. Gurevich, R. Halperin et al., The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study, Anticancer Res, vol.22, issue.2B, pp.1231-1239, 2002.

M. Morita, R. Yamaguchi, M. Tanaka, G. M. Tse, M. Yamaguchi et al., Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes, J Clin Pathol, 2016.

Z. C. Hartman, X. Y. Yang, O. Glass, G. Lei, T. Osada et al., HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis, Cancer Res, vol.71, issue.13, pp.4380-91, 2011.

M. I. Vazquez, J. Catalan-dibene, and A. Zlotnik, B cells responses and cytokine production are regulated by their immune microenvironment, Cytokine, vol.74, issue.2, pp.318-344, 2015.

M. Walter, S. Liang, S. Ghosh, P. J. Hornsby, and R. Li, Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells, Oncogene, vol.28, issue.30, pp.2745-55, 2009.

N. M. Iyengar, C. A. Hudis, and A. J. Dannenberg, Obesity and inflammation: new insights into breast cancer development and progression, Am Soc Clin Oncol Educ Book, vol.2013, pp.46-51

X. Jiang and D. J. Shapiro, The immune system and inflammation in breast cancer, Mol Cell Endocrinol, vol.382, issue.1, pp.673-82, 2014.

J. A. Coronella, P. Telleman, G. A. Kingsbury, T. D. Truong, S. Hays et al., Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer, Cancer Res, vol.61, issue.21, pp.7889-99, 2001.

Y. T. Chen, D. S. Ross, R. Chiu, X. K. Zhou, Y. Y. Chen et al., Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers, PLoS One, vol.6, issue.3, p.17876, 2011.

F. O. Ademuyiwa, W. Bshara, K. Attwood, C. Morrison, S. B. Edge et al., NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer, PLoS One, vol.7, issue.6, p.38783, 2012.

H. Wang, M. Sang, C. Geng, F. Liu, L. Gu et al., MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelialmesenchymal transition, Neoplasma, vol.63, issue.1, pp.44-56, 2016.

S. Luen, B. Virassamy, P. Savas, R. Salgado, and S. Loi, The genomic landscape of breast cancer and its interaction with host immunity, Breast, vol.29, pp.241-50, 2016.

J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells, Nat Immunol, vol.4, issue.4, pp.330-336, 2003.

A. Facciabene, G. T. Motz, and G. Coukos, T-regulatory cells: key players in tumor immune escape and angiogenesis, Cancer Res, vol.72, issue.9, pp.2162-71, 2012.

D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape, Curr Opin Immunol, vol.27, pp.16-25, 2014.

M. Yang, T. Moriya, M. Oguma, D. Cruz, C. Endoh et al., Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases, Pathol Int, vol.53, issue.7, pp.422-430, 2003.

M. Mori, K. Tsugawa, H. Yamauchi, H. Yagata, K. Suzuki et al., Pathological assessment of microinvasive carcinoma of the breast, Breast Cancer, vol.20, issue.4, pp.331-336, 2013.

S. A. Silver and F. A. Tavassoli, Mammary ductal carcinoma in situ with microinvasion, Cancer, vol.82, issue.12, pp.2382-90, 1998.

D. N. Margalit, M. Sreedhara, Y. H. Chen, P. J. Catalano, P. L. Nguyen et al., Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy, Ann Surg Oncol, vol.20, issue.3, pp.811-819, 2013.

L. Wang, W. Zhang, S. Lyu, X. Liu, T. Zhang et al., Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast, Tumour Biol, vol.36, issue.4, pp.2241-2249, 2015.

L. J. Solin, B. L. Fowble, I. T. Yeh, M. J. Kowalyshyn, D. J. Schultz et al., Microinvasive ductal carcinoma of the breast treated with breastconserving surgery and definitive irradiation, Int J Radiat Oncol Biol Phys, vol.23, issue.5, pp.961-969, 1992.

I. De-mascarel, G. Macgrogan, S. Mathoulin-pelissier, I. Soubeyran, V. Picot et al., Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas, Cancer, vol.94, issue.8, pp.2134-2176, 2002.

C. G. Kuhar and E. Matos, Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report, BMC Res Notes, vol.7, p.325, 2014.